TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05666115

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic group
Description: During the first 4 weeks, patients will be instructed to take two capsules of Enterelle plus (Bromatech lab, Manno, Switzerland) during morning time, before or after breakfast. Enterelle plus contains specific strains, i.e., S boulardi, E faecium, and acidophilus, that contribute to reduce the mycotic flora and modulate the gastrointestinal transit. For the next 8 weeks, participants will be told to ingest two capsules of Adomelle (Bromatech lab, Manno, Switzerland) at night, during or right after dinner. Adomelle contains several strains, including Bifidobacterium breve, that help to reduce abdominal fat, pain, and gas, and control the frequency of deposition

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise group
Description: This type of intervention has shown to benefit patients with several chronic conditions 23, including axSpA 13. Exercises combined high knees, lunges, basic burpees, plank, skipping, mountain climbers, and squats with jumps. The training routine will be conducted three times per week, and each session will last around 8 minutes (2 sets of 4 minutes, with a 10 second rest between them). All sessions will be individually tailored and supervised by a senior professional with a degree in Physiotherapy and Sciences of Physical Activity and Sport. Overall, participants will be told to continue exercising if low to moderate bearable pain appeared during training.
Study: NCT05253326

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation Exercises
Description: It is among the relaxation techniques that require the active participation of the individual.
Study: NCT05779943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: F18-rhPSMA-7.3
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT scan
Study: NCT06154408

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acids
Description: The active treatment, supplied by Soloways, LLC., contained omega-3 fatty acids (1000 mg of fish oil, of which 600 mg were eicosapentaenoic acid and 300 mg docosahexaenoic acid) per capsule. The subjects will take 2 capsules daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsules identical in appearance, matched for color coating, shape, and size with omega-3 fatty acids capsule
Study: NCT05169931

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RegenerEyes
Description: Biologic eye drop
Study: NCT06042231

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Exercise and education intervention. Participants will be prescribed a tailored exercise program to complete before ('pre-habilitation') and after their AF ablation procedure (rehabilitation).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education Intervention
Description: Education intervention. Participants will be given a 1-1 education session (up to 3 sessions) before and after their AF ablation procedure. Participants will be given behavioural strategies to improve adherence and compliancec to risk-factor modification.
Study: NCT05154890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegtarviliase IV
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegtarviliase SC
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegtarviliase SC
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegtarviliase SC
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegtarviliase SC
Description: Administered SC
Study: NCT06289296

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fatty acid intake in lean and obese males
Description: Acute and chronic intake of MCT and LCT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fatty acid intake in lean and obese males
Description: Acute and chronic intake of MCT and LCT
Study: NCT06562959

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluid Restriction Program
Description: In order to design the fluid restriction program content (booklet). The fluid restriction program included (a) General small-group discussion sessions, (b) individualized consultations, and (c) follow-up sessions. In the group discussion sessions, children in both the study and control groups were divided into subgroups (6 participants per each). In the group discussion sessions, children in both the study and control groups were divided into subgroups. The sessions were conducted in the meeting room of the Hemodialysis unit lasts for 45 minutes. In the Individualized Consultations, children then were provided tailored, age-appropriate education. The researchers also arranged for regular follow-up for one months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Bundle (Fluid Restriction Program and Auricular Acupressure
Description: the study group received the Fluid Restriction Program and Auricular Acupressure in four acupoints namely, Shenmen, Kidney Concha, Point Zero and Upper Tragus. The researcher's finger gently pressed on each determined acupoints in a circular movement with a clockwise direction for three minutes.
Study: NCT06439238

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ventilated non-menthol cigarettes
Description: a 4-week intervention where participants will be using ventilated non-menthol cigarettes.~Weekly telehealth visits will be conducted during baseline and the 4 weeks on study cigarettes to collect study measures followed by a follow-up one month after end of intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: minimally ventilated non-menthol cigarettes
Description: a 4-week intervention where participants will be using minimally ventilated non-menthol cigarettes.~Weekly telehealth visits will be conducted during baseline and the 4 weeks on study cigarettes to collect study measures followed by a follow-up one month after end of intervention.
Study: NCT06272617

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: verum acupuncture
Description: a type of acupuncture which is useful

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture
Description: a type of acupuncture which is useless
Study: NCT06468254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin
Description: Statin Group: Conventional chemotherapy and maintenance therapy combined with statins.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: Control Group: Conventional chemotherapy and maintenance therapy alone.
Study: NCT06389448

Intervention type: DEVICE
Group type: OTHER
Intervention: pCLE-gastr
Description: After identifying the location of the lesion through white light endoscopy, the pCLE operation is performed to acquire images from the specific gastric lesions, and finally the ESD routine is performed.
Study: NCT04914416

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Verum T1
Description: Verum T1 is a placebo: microcristalline cellulose. Daily dosage is 1000 mg in 3 capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T1
Description: Verum T1 is a placebo: microcristalline cellulose. Daily dosage is 1000 mg in 3 capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T1
Description: Verum T1 is a placebo: microcristalline cellulose. Daily dosage is 1000 mg in 3 capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T1
Description: Verum T1 is a placebo: microcristalline cellulose. Daily dosage is 1000 mg in 3 capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T1
Description: Verum T1 is a placebo: microcristalline cellulose. Daily dosage is 1000 mg in 3 capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T1
Description: Verum T1 is a placebo: microcristalline cellulose. Daily dosage is 1000 mg in 3 capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T1
Description: Verum T1 is a placebo: microcristalline cellulose. Daily dosage is 1000 mg in 3 capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T1
Description: Verum T1 is a placebo: microcristalline cellulose. Daily dosage is 1000 mg in 3 capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Verum T1
Description: Verum T1 is a placebo: microcristalline cellulose. Daily dosage is 1000 mg in 3 capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T1
Description: Verum T1 is a placebo: microcristalline cellulose. Daily dosage is 1000 mg in 3 capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T1
Description: Verum T1 is a placebo: microcristalline cellulose. Daily dosage is 1000 mg in 3 capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T1
Description: Verum T1 is a placebo: microcristalline cellulose. Daily dosage is 1000 mg in 3 capsules.
Study: NCT05105243

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CVN766
Description: highly selective orexin-1 receptor (Ox1R) antagonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CVN766
Description: highly selective orexin-1 receptor (Ox1R) antagonist
Study: NCT05581407

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TETRALITE
Description: LiteVax Adjuvanted Seasonal Influenza Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TETRALITE
Description: LiteVax Adjuvanted Seasonal Influenza Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TETRALITE
Description: LiteVax Adjuvanted Seasonal Influenza Vaccine
Study: NCT03192007

Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging
Description: Investigate anatomic and functional characteristics of transplant kidneys using MRI

Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging
Description: Investigate anatomic and functional characteristics of transplant kidneys using MRI
Study: NCT04819386

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active vision therapy sessions with the NEIVATECH Virtual Reality-based system
Description: The active visual therapy sessions with the NEIVATECH Virtual Reality-based system will be 18 in total, will have an average duration of half an hour and will be distributed over a month as follows: 5 sessions in the first two weeks after enrollment (Monday to Friday) and 4 sessions in the next two weeks (Monday to Thursday).
Study: NCT04914416

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T1
Description: Verum T1 is a placebo: microcristalline cellulose. Daily dosage is 1000 mg in 3 capsules.
Study: NCT04704076

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ESVS
Description: Breastfeeding with up to 59-mL formula daily for the first 30 days, followed by exclusive breastfeeding through 6 months of age
Study: NCT04124315

Intervention type: OTHER
Intervention: Accelerometry
Description: Patients will be given accelerometers at this visit and informed on how to use them (e.g., wear on the ankle during waking hours, upright, etc).

Intervention type: OTHER
Intervention: Daynamica app
Description: Participants will be asked to record location/activity on the app in order to characterize activity patterns both inside and outside of the hospital SET setting.
Study: NCT04704076

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exclusive breastfeeding
Description: Breastfeeding exclusively without any other food or fluid except vitamins, minerals and medications through 6 months of age
Study: NCT05111769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human brain natriuretic peptide
Description: 1. To determine the effect of rhBNP on hemodynamics in sepsis based on PiCCO hemodynamic monitoring; 2. To collect and sort out the relevant data to determine the effects of rhBNP on cardiac function and kidney function, including cardiac ultrasound, kidney blood flow index and related laboratory tests. 3. To determine the effect of rhBNP on the final prognosis of patients, including ICU mortality and hospital mortality, ICU time, hospital stay, ventilator use time, kidney replacement therapy time, vasoactive drug dosage and time.
Study: NCT04917419

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Luminotherapy and /or Psychoeducation Program
Description: TO complete

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Luminotherapy and /or Psychoeducation Program
Description: TO complete
Study: NCT04914416

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T1
Description: Verum T1 is a placebo: microcristalline cellulose. Daily dosage is 1000 mg in 3 capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T1
Description: Verum T1 is a placebo: microcristalline cellulose. Daily dosage is 1000 mg in 3 capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T1
Description: Verum T1 is a placebo: microcristalline cellulose. Daily dosage is 1000 mg in 3 capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T1
Description: Verum T1 is a placebo: microcristalline cellulose. Daily dosage is 1000 mg in 3 capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Verum T2
Description: Verum T2 is a 11500AAIU/g white kidney bean extract. Daily dosage is 1000 mg in 3 capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T2
Description: Verum T2 is a 11500AAIU/g white kidney bean extract. Daily dosage is 1000 mg in 3 capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T2
Description: Verum T2 is a 11500AAIU/g white kidney bean extract. Daily dosage is 1000 mg in 3 capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T2
Description: Verum T2 is a 11500AAIU/g white kidney bean extract. Daily dosage is 1000 mg in 3 capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T2
Description: Verum T2 is a 11500AAIU/g white kidney bean extract. Daily dosage is 1000 mg in 3 capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T2
Description: Verum T2 is a 11500AAIU/g white kidney bean extract. Daily dosage is 1000 mg in 3 capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T2
Description: Verum T2 is a 11500AAIU/g white kidney bean extract. Daily dosage is 1000 mg in 3 capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T2
Description: Verum T2 is a 11500AAIU/g white kidney bean extract. Daily dosage is 1000 mg in 3 capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Verum T2
Description: Verum T2 is a 11500AAIU/g white kidney bean extract. Daily dosage is 1000 mg in 3 capsules.
Study: NCT04671680

Intervention type: DEVICE
Intervention: LiDCO CNAP Monitoring Equipment
Description: A continuous non-invasive arterial blood pressure monitor for rapidly changing hemodynamics.
Study: NCT05452746

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Unilateral and bilateral acupuncture points:~Du 20 and GV 29,39 MS1, MS2, MS3 and MS4,40~Location of points:~Number of needles: 9~Depth of insertion:~MS1, MS2, MS3: insert the needle obliquely in the frontal direction for 1 cm Du 20: insert the needle obliquely in the frontal direction for 0.5 cm GV 29: insert the needle obliquely and downward for 0.5 cm Needles retained for 20 min Needle type: Han Yi 0.25x25 mm Treatment regimen: once per day for 2 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Inpatient psychiatric care for depression
Study: NCT05552638

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telecare
Description: The University of Kentucky (UK) will embed telehealth stations at community-based senior centers. Individuals who utilize these telehealth stations will be invited to complete a demographic survey prior to their telehealth appointment. Following their appointment, they will be invited to complete a semi-structured interview with the research team. Participants who elect to use telehealth station will be doing so as telehealth visits already scheduled with patients as Standard of Care (SOC). The telehealth station in the senior center will be used to increase ease and access to telehealth should the patient/provider choose to use such an approach (for example, in instances when the patient does not have sufficient technology, internet access, or capability to operate telehealth at home).
Study: NCT04965714

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegargiminase
Description: Given IM

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Undergo surgical resection
Study: NCT04914416

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T2
Description: Verum T2 is a 11500AAIU/g white kidney bean extract. Daily dosage is 1000 mg in 3 capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T2
Description: Verum T2 is a 11500AAIU/g white kidney bean extract. Daily dosage is 1000 mg in 3 capsules.
Study: NCT06134128

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivationally Enhanced Compensatory Cognitive Training for Addictions Group
Description: 8-week manualized group-based behavioral intervention delivered via telehealth
Study: NCT05001958

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action observation
Description: Participants will view a video of a task performed by a non-disabled actor and then the participants perform the task from the video with their weaker arm \& hand.
Study: NCT04939571

Intervention type: OTHER
Intervention: Registry of preterm born infants with treatment-requiring ROP
Description: All prematurely born infants who develop treatment requiring ROP and are treated (independent of the kind of treatment modality) at a center that participates in the registry are eligible for database entry.
Study: NCT05257564

Intervention type: DEVICE
Group type: OTHER
Intervention: Determine the accuracy of quantitative measurements of GLU, HbA1c,CHOL and CRE with POC devices compared to a laboratory reference method (Roche)
Description: Fingerstick capillary blood will be collected according to each manufacturer's Instructions for use. The fingerstick capillary blood samples will be used immediately on the point-of-care assays. The venous blood will be collected in specific tubes for plasma (GLU), for whole blood (HbA1c) and for serum (CREP, CHOL). Plasma will be separated by centrifugation at the PHC facility and health post and aliquots will be prepared. Serum will be left to clot prior to centrifugation and serum aliquots will be prepared at the PHC facility and health post. The samples will be stored until transfer to the BPKIHS reference lab.
Study: NCT05449262

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: functional resistance training GROUP A
Description: Session of 45-60 min. Warm up prior to training Warm up 6-7 min of mild cardiovascular exercise followed by 3-4 min stretching~Cool down post training A cool-down of 1 min of mild cardiovascular exercise followed by 4 min of stretching

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: functional resistance training GROUP B
Description: Session of 45-60 min Warm up prior to training Warm up 6-7 min of mild cardiovascular exercise followed by 3-4 min stretching~Cool down post training A cool-down of 1 min of mild cardiovascular exercise followed by 4 min of stretching
Study: NCT06291207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-224A
Description: PO, Once daily, 8weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-224B
Description: PO, Once daily, 8weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AD-224C
Description: PO, Once daily, 8weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of AD-224A
Description: PO, Once daily, 8weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of AD-224A
Description: PO, Once daily, 8weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of AD-224B
Description: PO, Once daily, 8weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of AD-224B
Description: PO, Once daily, 8weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of AD-224C
Description: PO, Once daily, 8weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of AD-224C
Description: PO, Once daily, 8weeks
Study: NCT05684614

Intervention type: OTHER
Intervention: Negative mood induction procedure
Description: The negative mood induction procedure (MIP) used in this study has previously been shown to effectively induce sadness. This MIP takes place in a virtual environment of an urban park and includes the following methods to induce negative mood: 1) Velten's tasks, consisting of interactive phrase formulations with negative thoughts and beliefs about the self (e.g., I don't have any future); 2) visualizing International Affective Pictures; and 3) recalling a negative autobiographical memory related to a significant loss (e.g., a person, a pet).

Intervention type: OTHER
Intervention: Spontaneous emotion regulation task
Description: Participants are instructed to use whatever strategy they want by doing, saying, and/or thinking whatever they want to feel better for 2 min

Intervention type: OTHER
Intervention: Positive mood induction procedure
Description: The positive mood induction procedure (MIP) used in this study has previously been shown to effectively induce sadness. This MIP takes place in a virtual environment of an urban park and includes the following methods to induce positive mood: 1) Velten's tasks, consisting of interactive phrase formulations with positive thoughts and beliefs (e.g., Life is wonderful); 2) visualizing International Affective Pictures; and 3) recalling a positive autobiographical memory
Study: NCT06358703

Intervention type: DRUG
Intervention: Caplacizumab
Description: Early Caplacizumab use
Study: NCT05206435

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Cigarette
Description: Electronic Cigarettes are provided to replace tobacco cigarettes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Lozenge
Description: Nicotine Lozenges are provided to replace tobacco cigarettes
Study: NCT06299163

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NM32-2668
Description: Anti-ROR1/Anti-Cluster of Differentiation 3 (CD3)/Anti-Human Serum Albumin (HSA) Tri-Specific Antibody